RATIONALE: Increasing evidence supports a key role for the transcription factor nuclear factor (NF)-kappaB in the host response to pneumococcal infection. Control of NF-kappaB activity is achieved through interactions with the IkappaB family of inhibitors, encoded by the genes NFKBIA, NFKBIB, and NFKBIE. Rare NFKBIA mutations cause immunodeficiency with severe bacterial infection, raising the possibility that common IkappaB gene polymorphisms confer susceptibility to common bacterial disease. OBJECTIVES: To determine whether polymorphisms in NFKBIA, NFKBIB, and NFKBIE associate with susceptibility to invasive pneumococcal disease (IPD) and thoracic empyema. METHODS: We studied the frequencies of 62 single-nucleotide polymorphisms (SNPs) across NFKBIA, NFKBIB, and NFKBIE in individuals with IPD and control subjects (n=1,060). Significantly associated SNPs were then studied in a group of individuals with thoracic empyema and a second control group (n=632). MEASUREMENTS AND MAIN RESULTS: Two SNPs in the NFKBIA promoter region were associated with protection from IPD in both the initial study group and the pneumococcal empyema subgroup. Significant protection from IPD was observed for carriage of mutant alleles at these two loci on combining the groups (SNP rs3138053: Mantel-Haenszel 2x2 chi2=13.030, p=0.0003; odds ratio [OR], 0.60; 95% confidence interval [CI], 0.45-0.79; rs2233406: Mantel-Haenszel 2x2 chi2=18.927, p=0.00001; OR, 0.55; 95% CI, 0.42-0.72). An NFKBIE SNP associated with susceptibility to IPD but not pneumococcal empyema. None of the NFKBIB SNPs associated with IPD susceptibility. CONCLUSIONS: NFKBIA polymorphisms associate with susceptibility to IPD. Genetic variation in an inhibitor of NF-kappaB therefore not only causes a very rare immunodeficiency state but may also influence the development of common infectious disease.
RATIONALE: Increasing evidence supports a key role for the transcription factor nuclear factor (NF)-kappaB in the host response to pneumococcal infection. Control of NF-kappaB activity is achieved through interactions with the IkappaB family of inhibitors, encoded by the genes NFKBIA, NFKBIB, and NFKBIE. Rare NFKBIA mutations cause immunodeficiency with severe bacterial infection, raising the possibility that common IkappaB gene polymorphisms confer susceptibility to common bacterial disease. OBJECTIVES: To determine whether polymorphisms in NFKBIA, NFKBIB, and NFKBIE associate with susceptibility to invasive pneumococcal disease (IPD) and thoracic empyema. METHODS: We studied the frequencies of 62 single-nucleotide polymorphisms (SNPs) across NFKBIA, NFKBIB, and NFKBIE in individuals with IPD and control subjects (n=1,060). Significantly associated SNPs were then studied in a group of individuals with thoracic empyema and a second control group (n=632). MEASUREMENTS AND MAIN RESULTS: Two SNPs in the NFKBIA promoter region were associated with protection from IPD in both the initial study group and the pneumococcal empyema subgroup. Significant protection from IPD was observed for carriage of mutant alleles at these two loci on combining the groups (SNP rs3138053: Mantel-Haenszel 2x2 chi2=13.030, p=0.0003; odds ratio [OR], 0.60; 95% confidence interval [CI], 0.45-0.79; rs2233406: Mantel-Haenszel 2x2 chi2=18.927, p=0.00001; OR, 0.55; 95% CI, 0.42-0.72). An NFKBIE SNP associated with susceptibility to IPD but not pneumococcal empyema. None of the NFKBIB SNPs associated with IPD susceptibility. CONCLUSIONS: NFKBIA polymorphisms associate with susceptibility to IPD. Genetic variation in an inhibitor of NF-kappaB therefore not only causes a very rare immunodeficiency state but may also influence the development of common infectious disease.
Authors: Elinor K Karlsson; Jason B Harris; Shervin Tabrizi; Atiqur Rahman; Ilya Shlyakhter; Nick Patterson; Colm O'Dushlaine; Stephen F Schaffner; Sameer Gupta; Fahima Chowdhury; Alaullah Sheikh; Ok Sarah Shin; Crystal Ellis; Christine E Becker; Lynda M Stuart; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri; Pardis C Sabeti; Regina C Larocque Journal: Sci Transl Med Date: 2013-07-03 Impact factor: 17.956
Authors: S J Chapman; C C Khor; F O Vannberg; A Rautanen; S Segal; C E Moore; R J O Davies; N P Day; N Peshu; D W Crook; J A Berkley; T N Williams; J A Scott; A V S Hill Journal: Genes Immun Date: 2009-10-01 Impact factor: 2.676
Authors: Stephen J Chapman; Fredrik O Vannberg; Chiea C Khor; Anna Rautanen; Nicholas A Maskell; Christopher W H Davies; Catrin E Moore; Nicholas P Day; Derrick W Crook; Robert J O Davies; Adrian V S Hill Journal: BMC Med Genet Date: 2010-01-15 Impact factor: 2.103
Authors: Xiaofei Gao; Fengyi Wan; Kristina Mateo; Eduardo Callegari; Dan Wang; Wanyin Deng; Jose Puente; Feng Li; Michael S Chaussee; B Brett Finlay; Michael J Lenardo; Philip R Hardwidge Journal: PLoS Pathog Date: 2009-12-24 Impact factor: 6.823
Authors: Athina Savva; Matthijs C Brouwer; Thierry Roger; Mercedes Valls Serón; Didier Le Roy; Bart Ferwerda; Arie van der Ende; Pierre-Yves Bochud; Diederik van de Beek; Thierry Calandra Journal: Proc Natl Acad Sci U S A Date: 2016-03-14 Impact factor: 11.205